Apellis Pharmaceuticals, Inc.

APLSNASDAQHealthcare

$41.03

+$0.00(+0.00%)

Market Cap$5.3B

P/E Ratio—

52W High$41.14

52W Low$16.61

Avg Volume6.4M

Open$41.05

Beta-0.25

Free Cash Flow Financials Revenue

Apellis Pharmaceuticals, Inc. (APLS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

APLS · free cash flow · updated Jun 8, 2026

Core FCF metrics

APLS · FCF · TTM · margin & CAGR

Free cash flow was $45.0M for FY2025 (fiscal year ending 2025-12-31), up 151.0% year-over-year The FCF margin was 4.5%.

FY2025 Free Cash Flow$45.0M▲ +151.0% YoY

Trailing 12M (TTM)$37.8Mtrailing 4 quarters sum

FCF Margin4.5%$45.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

APLS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$45.3M(0M)$45.0M▲ +151.0%4.5%

FY2024−$87.9M(0M)−$88.3M▲ +85.2%-11.3%

FY2023−$594.7M(1M)−$595.5M▼ 15.6%-150.2%

FY2022−$513.7M(2M)−$515.3M▲ +8.7%-683.2%

FY2021−$563.1M(1M)−$564.2M▼ 240.1%-847.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

APLS · P/FCF · FCF yield · FCF per share

Apellis Pharmaceuticals, Inc. (APLS) trades at a FCF yield of 0.72% and a price-to-free-cash-flow ratio of 136.8x. FCF per share stands at $0.30, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

0.72%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.30

TTM FCF ÷ Shares Outstanding

Price / FCF

x136.8

Share Price ÷ FCF per Share

EV / FCF (TTM)

x140.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

APLS · cash flow statement · operating / investing / financing

For FY2025, Apellis Pharmaceuticals, Inc. generated $45.3M in operating cash flow and spent 0M in capital expenditures, yielding $45.0M in free cash flow.

Operating Activities

+$45.3M

Cash from core business operations

2025-12-31

Investing Activities

−$0.3M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$8.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($45.3M) − |CapEx| (0M) = FCF ($45.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

APLS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Apellis Pharmaceuticals, Inc.YOU

APLS

$45.0M+151.0%4.5%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Apellis Pharmaceuticals, Inc. (APLS) reported free cash flow of $45.0M for FY2025 (fiscal year ending 2025-12-31), up 151.0% year-over-year. The FCF margin was 4.5%.

Based on available data, Apellis Pharmaceuticals, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $45.0M in FY2025.

Apellis Pharmaceuticals, Inc.'s FCF yield is 0.72% and price-to-FCF ratio is 136.8x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

APLS free cash flow · 8 questions

Apellis Pharmaceuticals, Inc. free cash flow was $45.0M for FY2025, up 151.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $37.8M.

APLS free cash flowAPLS FCFAPLS FCF 2025APLS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Apellis Pharmaceuticals, Inc. · Apellis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026